Tirzepatide Peptide - GIP/GLP-1 Dual Agonist

Tirzepatide for Research: Complete Scientific Overview

Tirzepatide represents a paradigm shift in incretin-based research. As a unimolecular dual agonist targeting both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, it offers unique pharmacological properties distinct from selective GLP-1 receptor agonists like Semaglutide. The peptide is engineered with a C20 fatty diacid moiety that enables strong albumin binding, resulting in an extended half-life of approximately 116 hours, making it suitable for once-weekly dosing in research protocols.

Mechanism of Action

Tirzepatide acts as a balanced dual agonist at the GIP and GLP-1 receptors with equipotent activity at both targets. The GIP component enhances first-phase insulin secretion, improves lipid metabolism, and exerts direct beneficial effects on adipocyte function. Meanwhile, the GLP-1 component promotes glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release from α-cells, delays gastric emptying, and activates central satiety pathways in the hypothalamus. The synergistic activation of both pathways provides complementary metabolic effects that are not achievable with either receptor agonist alone.

Research Applications

• Metabolic Syndrome Research: Investigating the integrated effects of dual incretin activation on glucose metabolism, lipid profiles, and body weight regulation
• Glucose Homeostasis Studies: Understanding GIP and GLP-1-mediated insulin secretion dynamics and glucagon suppression
• Lipid Metabolism Research: Exploring GIP's direct effects on adipose tissue function and lipid handling
• Cardiovascular Research: Studying the cardioprotective effects of dual incretin activation beyond glycemic control
• Comparative Receptor Pharmacology: Characterizing signaling bias and receptor internalization at GIPR vs GLP-1R
• Appetite Regulation: Investigating central GIPR and GLP-1R pathways in feeding behavior and energy expenditure
• Beta-Cell Function: Studying the combined effects of GIP and GLP-1 on β-cell survival, proliferation, and function

Structural Characteristics

Tirzepatide is a 39-amino acid peptide incorporating non-canonical amino acids including α-aminoisobutyric acid (Aib) at positions 2 and 13, which confer resistance to DPP-4 degradation. The peptide also features a C-terminal amide group that enhances stability and a C20 fatty diacid conjugated to lysine at position 20 via a linker, enabling reversible albumin binding for extended half-life. These structural features make Tirzepatide an excellent tool for long-term metabolic research studies.

Chemical Information

CAS Number: 2023788-19-2
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.5 g/mol
Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Purity: >99% (HPLC)
Form: Lyophilized powder
Storage: -20°C (lyophilized), 4°C (reconstituted)

Reconstitution and Handling Protocols

For optimal stability and research validity, Tirzepatide should be reconstituted with sterile bacteriostatic water or sterile saline. Allow the lyophilized powder to dissolve completely without vigorous shaking to maintain peptide integrity. Once reconstituted, the solution should be stored at 4°C and used within 30 days. Avoid repeated freeze-thaw cycles to preserve peptide structure and biological activity. For long-term storage, keep the lyophilized powder at -20°C away from light and moisture.